Evidence map›Paper›PMID 29970076›Full record

ArticleAnnals of clinical microbiology and antimicrobials2018

Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.

Dabesa Gobena, Gemechu Ameya, Kinfe Haile, Getaneh Abreha, Yoseph Worku, Tessema Debela

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 5 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Proportion and trend of primary resistance among Multidrug resistant Tuberculosis patients in Ethiopia.Journal of clinical tuberculosis and other mycobacterial diseases · 2022
    Article
  17. Observational
  18. Determinants of Multidrug-ResistantInfection and drug resistance · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Dabesa GobenaOromia Regional Health Bureau, Addis Ababa, Ethiopia.
Gemechu AmeyaDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Arba Minch University, P.O. Box: 21, Arba Minch, Ethiopia. gemechuameya@gmail.com.
Kinfe HaileSaint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Getaneh AbrehaEthiopia Public Health Institute, Addis Ababa, Ethiopia.
Yoseph WorkuSaint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Tessema DebelaOromia Regional Health Bureau, Addis Ababa, Ethiopia.
Oromiyaa Regional Health Bureau · ETSt. Paul's Hospital Millennium Medical College · ETArba Minch University · ETEthiopian Public Health Institute · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurable disease tuberculosis is becoming incurable or difficult to treat due to drug resistance. Multi drug resistance tuberculosis is a major health problem for less developed countries. Development of drug resistance is mainly as result of man related factors and poor lifestyle. Identifying predictors of drug resistance and working on them is the important way of reducing the expansion in high burden countries. Ethiopia is one of TB, TB/HIV, and multi-drug resistant tuberculosis (MDR-TB) high burden country globally. This study was aimed to assess predictor of MDR-TB in southwest part of Ethiopia.

methodsUnmatched case control study was conducted in case to control ratio of 1:1.2 in southwest part of Ethiopia. The cases were recruited from confirmed MDR-TB patient enrolled on second line treatment in Shenen Gibe Hospital (MDR-TB treatment center of the prefecture) and the controls were recruited from previously TB patients who cured or patient with smear negative at the end of treatment month during the study period in the same area. The data was collected by structured questionnaire by interview and logistic regression analyses were used to identify predictors of MDR-TB. Odds ratios with 95% CI were computed to determine the predictors.

resultFrom the total 132 participants about 45% of them were cases. None disclosed tuberculosis infected to relatives [AOR = 3.4, 95% CI (1.2-9.8)], insufficient instruction on how to take anti-TB drug [AOR = 4.7, 95% CI (1.4-14.6)], contact history with MDR-TB [AOR = 8.5, 95% CI (2.9-25.5)], interruption of first-line anti-TB treatment for at list 1 day [AOR = 7.9, 95% CI (2.5-24.9)], and having alcohol drinking habits [AOR = 5.1, 95% CI (1.4-18.7)] were identified predictors for MDR-TB infection in study area.

conclusionTB infection disclosure status, insufficient instruction on drug usage, contact history with MDR-TB, interruption of first-line anti-TB drugs, and alcohol drinking habits were identified predictor of MDR-TB case. Therefore, early detection and proper treatment of drug susceptible TB, strengthening directly observed treatment, short-course on daily bases, community involvement, and supporting the patient to intervene identified factors is paramount.

Indexed as

Drug Resistance, Multiple, BacterialAdolescentAdultAntitubercular AgentsCase-Control StudiesChildEarly DiagnosisEthiopiaFemaleHumansIsoniazidMaleMycobacterium tuberculosisRifampinSurveys and QuestionnairesTuberculosis, Multidrug-ResistantAntitubercular AgentsIsoniazidRifampinMulti-drug resistance tuberculosisPredictorSouthwest EthiopiaTuberculosis treatment

Identifiers

PMID29970076
PMCPMC6029339
OpenAlexW2809744609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.